Advertisement

Clinical and Experimental Nephrology

, Volume 23, Issue 2, pp 169–181 | Cite as

Comprehensive evaluation of the significance of immunofluorescent findings on clinicopathological features in IgA nephropathy

  • Ritsuko KatafuchiEmail author
  • Hiroshi Nagae
  • Kosuke Masutani
  • Kazuhiko Tsuruya
  • Koji Mitsuiki
Original article
  • 125 Downloads

Abstract

Background

The clinicopathological significance of immunofluorescent findings in IgA nephropathy remains controversial.

Methods

The relations of the deposition of IgA, IgG, IgM, C3, C1q and fibrinogen (Fib) with pathological findings, baseline clinical findings, and renal outcome were evaluated in 688 patients with IgA nephropathy. Pathological features included cellular or fibrocellular crescents, endocapillary or mesangial hypercellularity, segmental or global glomerulosclerosis and the Oxford classification.

Results

The median age at biopsy was 30 years. There were 289 men. With 74 months median follow-up, 32% of patients received steroids. Twelve percent of patients developed end-stage renal disease (ESRD). The degree of IgA was closely related to the degree of C3, IgG and IgM deposition. The degree of IgA, C3, IgG and Fib deposition was significantly related to the percentage of glomeruli with crescent, endocapillary and mesangial hypercellularity. IgM deposition showed significant association with crescent, mesangial hypercellularity, segmental sclerosis, global glomerulosclerosis and tubular atrophy/interstitial fibrosis. In the patients treated with steroids, the risk for ESRD in patients with 2–3+ IgA deposition was significantly lower with reference of 1+ IgA deposition.

Conclusion

We found the different roles of glomerular immune reactants’ deposition in the inflammatory process from acute to chronic stage. IgA deposition together with IgG, Fib and C3 may produce acute inflammatory injury. IgM deposition might occur in the early stage of inflammation and remains until late sclerotic stage. The prominent deposition of IgA related to low risk for ESRD in patients who received steroids might suggest effectiveness of steroids in such patients.

Keywords

IgA nephropathy Immunofluorescent study IgA deposition IgG deposition Complement deposition 

Notes

Acknowledgements

The authors are grateful to Mr. Mikio Munakata for technical assistance; cutting frozen section, staining sections for immunofluorescent study, and evaluating the intensity of deposition of IgG, IgA, IgM, C3, C1q and fibrinogen in all biopsies in this study.

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Ethical approval

All procedures performed in this study were in accordance with ethical standards of the Hospital Review Board (IRB)/Ethic Committees at National Fukuoka Higashi Medical Center and Fukuoka Red Cross Hospital (IRB approval numbers: 28–37 and 351, respectively) and with Ethical Guidelines for Medical and Health Research Involving Human Subjects by Ministry of Health, Labor and Welfare in Japan.

Informed consent

Since this was a retrospective study and used a preexisting database while employing the highest privacy policy standards, the investigators shall not necessarily be required to obtain informed consent. However, we made public information concerning this study on the web (http://www.fe-med.jp/ and http://www.fukuoka-med.jrc.or.jp/) and ensured the opportunities for the research subjects to refuse utilizing their personal information.

References

  1. 1.
    Schmekel B, Svalander C, Bucht H, Westberg NG. Mesangial IgA glomerulonephritis in adults. Clinical and histopathological observations. Acta Med Scand. 1981;210:363–72.CrossRefGoogle Scholar
  2. 2.
    Waldherr R, Rambausek M, Rauterberg W, Andrassy K, et al. Immunohistochemical features of mesangial IgA glomerulonephritis. Contrib Nephrol. 1984;40:99–106.CrossRefGoogle Scholar
  3. 3.
    Boyce NW, Holdsworth SR, Thomson NM, Atkins RC. Clinicopathological associations in mesangial IgA nephropathy. Am J Nephrol. 1986;6:246–52.CrossRefGoogle Scholar
  4. 4.
    Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: prognostic significance of proteinuria and histological alterations. Nephron. 1983;34:146–53.CrossRefGoogle Scholar
  5. 5.
    Wada Y, Ogata H, Takeshige Y, Takeshima A, et al. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol. 2013;17:73–82.CrossRefGoogle Scholar
  6. 6.
    Moriyama T, Shimizu A, Takei T, Uchida K, et al. Characteristics of immunoglobulin A nephropathy with mesangial immunoglobulin G and immunoglobulin M deposition. Nephrology (Carlton). 2010;15:747–54.CrossRefGoogle Scholar
  7. 7.
    Vangelista A, Frasca GM, Mondini S, Bonomini V. Idiopathic IgA mesangial nephropathy: immunohistological features. Contrib Nephrol. 1984;40:167–73.CrossRefGoogle Scholar
  8. 8.
    Shirai T, Tomino Y, Sato M, Yoshiki T, et al. IgA nephropathy: clinicopathology and immunopathology. Contrib Nephrol. 1978;9:88–100.CrossRefGoogle Scholar
  9. 9.
    D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine (Baltimore). 1985;64:49–60.CrossRefGoogle Scholar
  10. 10.
    Mustonen J, Pastemack A, Helin H, Nikkila M. Clinicopathologic correlations in a series of 143 patients with IgA glomerulonephritis. Am J Nephrol. 1985;5:150–7.CrossRefGoogle Scholar
  11. 11.
    Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis. 1988;12:348–52.CrossRefGoogle Scholar
  12. 12.
    Workin Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76:546–56.CrossRefGoogle Scholar
  13. 13.
    Workin Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76:534–45.CrossRefGoogle Scholar
  14. 14.
    Nasri H, Sajjadieh S, Mardani S, Momeni A, et al. Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy. J Nephropathol. 2013;2:190–5.Google Scholar
  15. 15.
    Haas M, Verhave JC, Liu ZH, Alpers CE, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017;28:691–701.CrossRefGoogle Scholar
  16. 16.
    Trimarchi H, Barratt J, Cattran DC, Cook HT, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91:1014–21.CrossRefGoogle Scholar
  17. 17.
    Katafuchi R, Ikeda K, Mizumasa T, Tanaka H, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003;41:972–83.CrossRefGoogle Scholar
  18. 18.
    Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N, et al. Glomerular score as a prognosticator in IgA nephropathy: its usefulness and limitation. Clin Nephrol. 1998;49:1–8.Google Scholar
  19. 19.
    Katafuchi R, Minomiya T, Mizumasa T, Ikeda K, et al. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transplant. 2008;23:3915–20.CrossRefGoogle Scholar
  20. 20.
    Shen XH, Liang SS, Chen HM, Le WB, et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015;28:441–9.CrossRefGoogle Scholar
  21. 21.
    Bellur SS, Troyanov S, Cook HT, Roberts IS. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant. 2011;26:2533–6.CrossRefGoogle Scholar
  22. 22.
    Shin DH, Lim BJ, Han IM, Han SG, et al. Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy. Mod Pathol. 2016;29:743–52.CrossRefGoogle Scholar
  23. 23.
    Tang Z, Wu Y, Wang QW, Yu YS, et al. Idiopathic IgA nephropathy with diffuse crescent formation. Am J Nephrol. 2002;22:480–6.CrossRefGoogle Scholar
  24. 24.
    Maillard N, Wyatt RJ, Julian BA, Kiryluk K, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26:1503–12.CrossRefGoogle Scholar
  25. 25.
    Kim SJ, Koo HM, Lim BJ, Oh HJ, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLos One. 2012;7:e40495:1–13.CrossRefGoogle Scholar
  26. 26.
    Sinniah R, Javier AR, Ku G. The pathology of mesangial IgA nephritis with clinical correlation. Histopathology. 1981;5:469–90.CrossRefGoogle Scholar
  27. 27.
    Lee HJ, Choi SY, Jeong KH, Sung JY, et al. Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol. 2013;80:98–104.CrossRefGoogle Scholar
  28. 28.
    Tazoe N. Significance of deposition of fibrin related antigen in the glomeruli of IgA nephropathy patients. Jpn J Nephrol. 1987;29:1181–8.Google Scholar
  29. 29.
    Liu N, Ono T, Suyama K, Nogaki F, et al. Mesangial factor V expression colocalized with fibrin deposition in IgA nephropathy. Kidney Int. 2000;58:598–606.CrossRefGoogle Scholar
  30. 30.
    Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17:1724–34.CrossRefGoogle Scholar
  31. 31.
    Espinosa M, Ortega R, Gomez-Carrasco JM, Lopez-Rubio F, et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant. 2009;24:886–91.CrossRefGoogle Scholar
  32. 32.
    Liu LL, Liu N, Chen Y, Wang LN, et al. Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. Clin Exp Immunol. 2013;174:152–60.CrossRefGoogle Scholar
  33. 33.
    Faria B, Henriques C, Matos AC, Daha MR, et al. Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathyprogression. Clin Exp Immunol. 2015;179:354–61.CrossRefGoogle Scholar
  34. 34.
    Espinosa M, Ortega R, Sanchez M, Segarra A, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9:897–904.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Ritsuko Katafuchi
    • 1
    Email author
  • Hiroshi Nagae
    • 1
  • Kosuke Masutani
    • 2
  • Kazuhiko Tsuruya
    • 3
  • Koji Mitsuiki
    • 4
  1. 1.Kidney UnitNational Fukuoka-Higashi Medical CenterKogaJapan
  2. 2.Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of MedicineFukuoka UniversityFukuokaJapan
  3. 3.Department of NephrologyNara Medical UniversityNaraJapan
  4. 4.Kidney UnitFukuoka Red Cross HospitalFukuokaJapan

Personalised recommendations